SV-40 is documented to have contaminated some polio vaccine preparations between 1955 and 1963. Epidemiological studies are underway attempting to prove a causal relationship between SV-40 and certain cancers, such as mesothelioma, osteosarcoma, and non-Hodgkin’s lymphoma. ViraCor’s quantitative PCR assay is used to detect the presence of SV-40 DNA in biological specimens.
See below for additional SV-40 assay and pathogen-specific information. For online ordering methods click here or contact us.
Assay Sheet
Test ID
3000 SV-40 Real-time qPCR
CPT Code
87799
Clinical Utility
SV-40 is documented to have contaminated some polio vaccine preparations between 1955 and 1963. Epidemiological studies are underway attempting to prove a causal relationship between SV-40 and certain cancers such as mesothelioma, osteosarcoma, and non-Hodgkin’s lymphoma. Quantitative SV-40 DNA PCR can be used to test for the presence of SV-40 DNA in biological specimens.
Procedure
Extraction of SV-40 viral DNA from plasma, other biological fluids, or tissues followed by amplification and detection using real-time, quantitative PCR. An internal control is added to ensure the extraction was performed correctly and the PCR reaction was not inhibited.
Specimens
Whole Blood: 3-5 ml submitted in an EDTA tube; ship ambient. CSF: 1 ml fluid frozen; submitted in a sterile, leakproof tube; ship on dry ice. Urine: 5 ml submitted in a sterile urinalysis container; ship ambient. Other: Please inquire.
Specificity
The primers and probes used in this assay are specific for SV-40 based on similarity search algorithms. Additionally, no cross reactivity was detected when tested against adenoviruses, BKV, CMV, EBV, HSV-1, HSV-2, HHV-6 variant A, HHV-6 variant B, HHV-7, HHV-8, JCV, Parvovirus B19, and VZV.
PCR tests are performed pursuant to a license agreement with Roche Molecular Systems, Inc.
This assay was developed and the performance characteristics were determined at ViraCor Laboratories. This test is performed in a CLIA certified laboratory. FDA approval is not required for the performance of this test.
AS11-0108
Pathogen Overview
ABOUT THE SV-40 VIRUS
SV-40 is a member of the Polyomaviridae family, along with BK virus (BKV) and JC virus (JCV). They are small, nonenveloped viruses with a closed, circular double-stranded DNA genome. Polyomaviruses are ubiquitous in nature and can be isolated from a number of species.
SV-40 was discovered in 1960 and has frequently been used in medical research because of its high oncogenicity and potent transforming capacity. It is unclear how SV-40 infection originated in humans, but it is known that potentially contaminated polio vaccines derived from rhesus monkey kidney cells were administered to approximately 98 million people in the United States between 1955 and 1963. It is estimated that up to one-third of these vaccines could have been contaminated with infectious SV-40. However, infections in individuals who did not receive polio vaccines and recent data supporting the transmission of HIV from monkeys to humans, suggest that other modes of transmission are involved.
SV-40 CLINICAL MANIFESTATIONS
SV-40 is asymptomatic in monkeys, however, it transforms cultured human cells and produces tumors when injected into newborn rodents. SV-40 DNA has been discovered in human tumors, specifically in mesotheliomas, brain tumors, osteosarcomas, choroids plexus tumors and ependyomas. The presence of SV-40 in human mesotheliomas and other human tumors has been confirmed by the work of more than 26 research groups. However, the role of SV-40 as a pathogen in the human population continues to be debated.
There is little published data on the role of SV-40 infections in transplant patients. One report found specific neutralizing antibodies to SV-40 in 18% of adult renal transplant patients. More recently, clinical studies have isolated SV-40 in allografts of children who underwent renal transplantation, as well as in the blood, urine and kidneys of people with focal segmental glomerulosclerosis, a known cause of end stage renal disease.
SV-40 LABORATORY DIAGNOSIS
Serological analysis has proved helpful for epidemiological purposes, but is not conclusive in diagnosing clinical syndromes. Unfortunately, there is considerable cross reactivity between SV-40 and BKV antibodies. Real-time PCR is a sensitive method for detecting the presence of SV-40 DNA, allowing further research into possible disease manifestations of the virus. Standardization of serological assays and molecular assays for SV-40 could assist researchers in understanding and drawing conclusions regarding the role of SV-40 in rare cancers.
Selected References
Demeter LM. JC, BK, and other polyomaviruses; progressive multifocal leukoencephalopathy. In: Mandell GL, Bennett JE, Dolin, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. Vol 2. 4th ed. New York, NY: Churchill Livingstone; 1995:1400-1406.
Knipe D, Howley P. Fields Virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
Kwak EJ, Vilchez RA, Randhawa P, Shapiro R, Butel JA, et al. Pathogenesis and management of polyomavirus infection in transplant recipients. Clin Infect Dis. 2002;(35):1081-1087.
Rizzo P, Bocchetta M, Powers A, Foddis R, Stekala E, et al. SV-40 and the pathogenesis of mesothelioma.
Cancer Biol. 2001;(11):63-71.
Wong M, Pagano JS, Schiller JT, Tevethia SS, Raab-Traub N, et al. New associations of human papillomavirus, simian virus 40, and epstein-barr virus with human cancer. J Natl Cancer Inst. 2002;(94):1832-1836.
PAO-13-0707 PCR tests are performed pursuant to a license agreement with Roche Molecular Systems, Inc.
2-3 ml separated from whole blood collected in EDTA (lavender top) tube.
Ship at ambient temperature Monday-Friday
Whole Blood
3-5 ml collected in EDTA (lavender top) tube. Do not freeze.
Ship at ambient temperature Monday-Friday
ImmuKnow®Specimens- Whole Blood
2-3 ml collected in a sodium heparin (green top) tube. Maintain temperature by shipping the specimen in 2 inch thick styrofoam with specimen surrounded by ambient temperature gel packs.
Ship ambient for priority overnight delivery Monday‐Friday
Specimen must arrive at ViraCor within 30 hours of collection.
Hepatitis Specimens- Whole Blood
7-10 ml in EDTA, ACD Solution A, or PPT sterile tube. Minimum specimen requirement is 2 ml plasma. Separate plasma from cells within 4 hours of collection and freeze. To remove plasma from cells, centrifuge at 1000 xg for 10-15 minutes. Do not clarify by filtration or further centrifugation. If specimen was collected in PPT tube, the entire tube can be frozen if desired following centrifugation.
Ship ambient or frozen
Monday-Friday
Body fluid other than blood or urine
Collect 2-3 ml in a sterile screw-cap tube.
Ship at ambient temperature Monday-Friday
Bone Marrow
1-2 ml, collected in an EDTA (lavender top) tube. Do not freeze.
Ship at ambient temperature Monday-Friday
Bronchial Lavage/Bronchial Wash
2-3 ml, collected in sterile screw-cap tube.
Ship at ambient temperature Monday-Friday
CSF
1-1.5 ml in sterile screw-cap tube. Freeze prior to shipment.
Ship on DRY ICE
Monday-Friday
Eye swab
Swab the inflamed conjunctiva or corneal lesions. Place swab in 1-2 ml sterile saline or viral transport media in sterile screw-cap tube.
Ship at ambient temperature Monday-Friday
Fecal
Sterile swab (plastic shaft only) or very small (pea size) fecal sample placed in 1-2 ml sterile saline or viral transport in sterile screw-cap tube.
Ship at ambient temperature Monday-Friday
Nasopharyngeal Aspirate/Tracheal Aspirate
2-3 ml collected in sterile saline in sterile screw-cap tube.
Ship at ambient temperature Monday-Friday
Nasopharyngeal Swab
Sterile swab (flexible shaft) placed in 1-2 sterile saline or viral transport media in sterile screw-cap tube. Do not use calcium alginate swab.
Ship at ambient temerpature Monday-Friday
Swab
Sterile swab (plastic shaft only) placed in 1-2 ml sterile saline or viral transport media in sterile screw-cap tube. Do not use calcium alginate swab.
Ship at ambient temperature Monday-Friday
Tissue
Place in a sterile screw-top container, add a small amount of saline to keep moist.
Ship at ambient temperature Monday-Friday Frozen tissue is acceptable
Urine
5 ml sample collected in a sterile urinalysis container. Transfer to a 15 ml sterile screw-cap tube for shipment.
Ship at ambient temperature Monday-Friday
Vesicular Lesion
Collect fluid and cellular material from the base of several fresh vesicles. Place swab in 1-2 mil sterile saline or viral transport media in sterile screw-cap tube. Do not use calcium alginate swab.
Ship at ambient temperature Monday-Friday
Other Specimen
Please inquire.
Shipping
All specimens must be labeled with patient's name and collection date.
A ViraCor Test Request Form must accompany each specimen.
Ship specimens FedEx Priority Overnight to: ViraCor Laboratories | 1001 NW Technology Dr | Lee's Summit MO 64086
PCR tests are performed pursuant to a license agreement with Roche Molecular Systems Inc.
ImmuKnow is a registered trademark of Cylex Incorporated.
Respiratory Viral Panel is a product of Luminex Corporation.
Abstracts & Publications
Kwak EJ, Vilchez RA, Randhawa P, et al. Pathogenesis and management of polyomavirus infection in transplant recipients. Clin Infect Dis. 2002;(35):1081-1087.
Polyomavirus (JC virus[JCV], BK virus [BKV], and simian virus 40 [SV40]) establish subclinical and persistent infections and share the capacity for reactivation from latency in their host under Immunosuppression. JCV establishes latency mainly in the kidney, and its reactivation results in the development of progressive multifocal leukoencephalopathy. BKV causes infection in the kidney and the urinary tract, and its activation causes a number of disorders, including nephropathy and hemorrhagic cystitis. Recent studies have reported SV40 in the allografts of children who received renal transplants and in the urine, blood, and kidneys of adults with focal segmental glomerulosclerosis, which is a cause of end-stage renal disease and an indication for kidney transplantation. Clinical syndromes related to polyomavirus infection are summarized in the present review, and strategies for the management of patients who receive transplants are discussed.
Rizzo P, Bocchetta M, Powers A, et al. SV-40 and the pathogenesis of mesothelioma. Semin Cancer Biol. 2001;(11):63-71.
Malignant mesothelioma, a tumor of the pleura, pericardium, and peritoneum, is presently a worldwide problem. Current therapy is ineffective in slowing the course of the disease, and median survival from the time of diagnosis is rarely greater than 1 year. While the tumor was almost unknown prior to the second half of the twentieth century, it is presently responsible for more than 2000 deaths per year in the US alone. Mesothelioma is frequently associated with exposure to asbestos, but the incidence of cases involving individuals with low levels of asbestos exposure is increasing. For this reason, there has been much interest in studying whether there are alternative factors that act alone or in conjunction with asbestos in producing this malignancy. In the last decade, simian virus 40 (SV40) has become the most notable suspected agent.
Wong M, Pagano JS, Schiller JT, et al. New associations of human papillomavirus, simian virus 40, and epstein-barr virus with human cancer. J Natl Cancer Inst. 2002;(94):1832-1836.
Approximately 15% of all cancers worldwide appear to be associated with viral infections, and several human DNA viruses are now accepted as causative factors of specific malignancies. Human papillomaviruses (HPVs) cause cervical and anogenital cancers. Epstein-Barr virus (EBV) causes infectious mononucleosis and is closely associated with Burkitt's lymphoma, nasopharyngeal carcinoma, and Hodgkin's disease. HPV is now associated with oral cancers, EBV with breast and gastric cancers, and simian virus 40 (SV40) with human mesothelioma and various brain and bone cancers. Several associations are not universally accepted, and their validity remains controversial. Consequently, the Biological Carcinogenesis Branch of the Division of Cancer Biology at the national Cancer Institute convened a workshop on March 12-13, 2001, in Bethesda, MD, to assess current knowledge concerning associations of HPV, SV40, and EBV with selected human cancers and to define areas where investigation is needed.